We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
At least five drug developers working on COVID-19 therapeutics and vaccines with U.S. government funding have contracts that bypass laws that ensure taxpayer-funded drugs and vaccines are affordable, a new report says. Read More
Japanese drugmaker Fujifilm is partnering with India’s Dr. Reddy’s and Dubai-based Global Response Aid (GRA) to manufacture and sell its influenza drug Avigan (favipiravir) for the treatment of COVID-19. Read More
In observance of the Independence Day holiday, Drug Industry Daily will not be published Friday, July 3. The next issue will be published Monday, July 6. Read More
The FDA hit a La Habra, California compounding pharmacy with a warning letter for repeated violations, including dirty equipment and the presence of insects. Read More
Inovio Pharmaceuticals has released data from the phase 1 clinical trial of its COVID-19 vaccine candidate showing it was safe and well-tolerated and induced immune responses in a majority of participants. Read More
The University of Oxford is resuming recruitment this week for its global clinical trial of hydroxychloroquine and chloroquine, which was paused after a now-retracted study found the antimalarial drugs had no benefit as a treatment for COVID-19. Read More
FDA Commissioner Stephen Hahn said yesterday that he was “optimistic” that more than one COVID-19 treatment could be available by the fall in addition to Gilead Sciences’ remdesivir, which has already received Emergency Use Authorization from the agency. Read More
Any COVID-19 vaccine the FDA approves would have to be at least 50 percent more effective than a placebo, according to a new guidance it released yesterday. Read More